

Jaclyn Beca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1849044/publications.pdf>

Version: 2024-02-01

6
papers

65
citations

1937457

4
h-index

2053595

5
g-index

6
all docs

6
docs citations

6
times ranked

58
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. <i>BMJ Open</i> , 2020, 10, e032884.	0.8	32
2	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110210.	0.5	10
3	Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. <i>Current Oncology</i> , 2021, 28, 4645-4654.	0.9	10
4	Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. <i>Clinical Oncology</i> , 2022, 34, e7-e17.	0.6	7
5	The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7072-7082.	1.3	4
6	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. <i>Current Oncology</i> , 2022, 29, 2046-2063.	0.9	2